Hims & Hers Stock Drops After Amazon Says It Will Offer Hair-Loss Treatments
Shares of Hims & Hers slid after Amazon.com said it would offer cheap treatments for concerns like hair loss, skin care and erectile dysfunction, directly competing with the telehealth startup. Amazon on Thursday launched the treatments through its One Medical telehealth service,
BofA lowered its rating of Hims & Hers (HIMS) to underperform from buy, citing Amazon’s (AMZN) push into the hair loss and ...
Walt Disney’s earnings beat Wall Street estimates, Super Micro Computer extends losses, and Cisco posts fiscal first-quarter ...
Hims & Hers (HIMS) is down -17.7%, or -$4.88 to $22.72. Published first on TheFly – the ultimate source for real-time, ...
Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.
Health and wellness platform Hims & Hers Health, Inc. (NYSE:HIMS), which has gained traction for its obesity-related ...
BofA downgraded Hims & Hers (HIMS) to Underperform from Buy with a price target of $18, down from $32. Amazon (AMZN) launched a cash-pay ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback